Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Cdx Report Program: Heterogeneity Revealed in Current Reporting Practices for Hemato-Oncology Companion Diagnostic (CDx) Markers in Multiple Countries

Sabit Delic, PhD, Piers Blombery, MBBS, María José Calasanz, PhD, Devon S. Chabot-Richards, MD, Dolors Colomer, PhD, Matteo G Della Porta, MD, Paul A S Evans, PhD, Torsten Haferlach, MD, Joanne Mason, FRCPath, Jay L Patel, MD, William S. Stevenson, MBBS, PhD, Christian Thiede, MD, Maria Teresa Voso, MD, Jordan Clark

Blood (2019) 134 (Supplement_1): 5837.

https://doi.org/10.1182/blood-2019-128652

Published: 2019

Journal Articles

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

Kristen Pettit, MD, Aaron T. Gerds, MD MS, Abdulraheem Yacoub, MD, Justin M. Watts, MD, Maciej Tartaczuch, MD, Terrence J Bradley, MD, Jake Shortt, MBBS FRACP FRCPA PhD, William S. Stevenson, MBBS,PhD, Natasha Joan Curtin, MDFRACP,FRCPA, James M. Rossetti, DO, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Georges Natsoulis, PhD, Amber Jones, MA, Moshe Talpaz, MD, Jennifer Peppe, BS, David M Ross, MD PhD, Hugh Young Rienhoff, Jr., MD

Blood (2019) 134 (Supplement_1): 556.

https://doi.org/10.1182/blood-2019-123244

Published: 2019

Journal Articles

In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial

Blood (2019) 134 (Supplement_1): 4247.

https://doi.org/10.1182/blood-2019-123921

Published: 2019

Journal Articles

mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node

Kyle R Crassini, MBBS, BSc, Yandong Shen, BMedSc (Hon), William S. Stevenson, MBBS, PhD, Stephen P. Mulligan, PhD, FRACP, FRCPA, MBBS, Oliver Giles Best, PhD BSc, Richard Christopherson, PhD Emeritus Professor

Blood (2018) 132 (Supplement 1): 1850.

https://doi.org/10.1182/blood-2018-99-118264

Published: 2018

Journal Articles

Treatment of Elderly and Unfit AML Patients with Prolonged Administration of Low Dose Cytarabine and Thioguanine Achieves High Complete Remission Rates in an Outpatient Setting

Christopher K Arthur, Anthony Jeffrey, Molly Forbes, Eva Yip, Vicki Katsioulas, William S. Stevenson, MBBS, PhD

Blood (2018) 132 (Supplement 1): 3998.

https://doi.org/10.1182/blood-2018-99-118027

Published: 2018

Journal Articles

Elevated LAG-3 Expression in the Tumor Microenvironement of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis

Colm Keane, MB BCh BAO PhD MBA, Soi C Law, PhD, Clare Gould, MBBS, Santiyagu Francis, PhD, Emad Uddin Abro, MBBS, FRACP, FRCPA, BSc(Hons), Joshua W.D. Tobin, MD, Simone Birch, MBBS, Grace Gifford, MD, Sara Gabreilli, William S. Stevenson, MBBS PhD, Dipti Talaulikar, PhD FRACP, FRCPA, MBBS, Anthony Gill, MD, Sanjiv Jain, MBBS, Donna Cross, Annette Hernadez, Sarah-Jane Halliday, Robert Bird, FRACP FRCP FRCPA MBBS MRCP, Mark Hertzberg, Maher K Gandhi, PhD

Blood (2018) 132 (Supplement 1): 1576.

https://doi.org/10.1182/blood-2018-99-112830

Published: 2018

Journal Articles

Deficiencies in Immunoglobulin Classes and Immunoglobulin G Subclasses Are Associated with Shorter Treatment Free Survival and Overall Survival in CLL

Kyle R Crassini, MBBS,BE,BSc, Eva Zhang, MBBS, Shalini Balendran, MBBS, Jane Freeman, BA,FRACP,FRCPA,MBBS,MPhil,MSc, Oliver Giles Best, PhDBSc, Cecily Forsyth, FRACP, FRCPA, MBBS, Naomi Mackinlay, Ping Han, MDPhD, William S. Stevenson, MBBS,PhD, Stephen Mulligan, PhDFRACP,FRCPA,MBBS

Blood (2017) 130 (Supplement 1): 5321.

https://doi.org/10.1182/blood.V130.Suppl_1.5321.5321

Published: 2017

Journal Articles

Analysis of mRNA Expression in Peripheral, Bone Marrow and Lymph Node Dervied CLL Cells Using the Nanosting Ncounter Platform

Kyle R Crassini, MBBS,BE,BSc, Yandong Shen, BMedSc (Hon), Richard Christopherson, PhDEmeritus Professor, William S. Stevenson, MBBS,PhD, Stephen Mulligan, PhDFRACP,FRCPA,MBBS, Oliver Giles Best, PhDBSc

Blood (2017) 130 (Supplement 1): 4279.

https://doi.org/10.1182/blood.V130.Suppl_1.4279.4279

Published: 2017

Journal Articles

Risk Stratification Combining MYC Immunohistochemistry with Standard IPI Has Utility in Patients with Diffuse Large B-Cell Lymphoma

David Simon Kliman, MBBS, Louise Imlay-Gillespie, BMed, Kirsten McIlroy, MBBS, FRCPA, Anthony Gill, MBBS, MD FRCPA, Christopher Arthur, MBBS, FRACP, FRCPA, Luke Coyle, MBBS, FRACP, FRCPA, Keith Fay, MBChB, FRACP, FRCPA, Ian H. Kerridge, MBBS, MPhil, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Stephen Mulligan, MBBS, PhD FRACP, FRCPA, William S Stevenson, MBBS, PhD FRACP, FRCPA, Christopher M Ward, MBChB, PhD FRACP, FRCPA, Matthew Greenwood, MBBS, FRACP, FRCPA

Blood (2015) 126 (23): 2656.

https://doi.org/10.1182/blood.V126.23.2656.2656

Published: 2015

Journal Articles

Homozygous Mutation of the ETS DNA-Binding Domain of FLI1 Causes a Bleeding Disorder with Giant Alpha Granules Similar to Paris-Trousseau Thrombocytopenia

William S Stevenson, MBBS, PhD FRACP, FRCPA, David John Rabbolini, BSc,MBBChir, Timothy Brighton, Joel Mackay, Christopher M Ward, MBChB, PhD FRACP, FRCPA, Marie-Christine Morel-Kopp, PhD

Blood (2015) 126 (23): 78.

https://doi.org/10.1182/blood.V126.23.78.78

Published: 2015

Journal Articles

Association Between RUNX3 Hypermethylation and Acute Myeloid Leukemia Inv(16) Subtype

Marcos R Estecio, PhD, Sirisha Maddipoti, MD, Courtney D. DiNardo, MD, Hui Yang, William S Stevenson, MBBS, PhD, Carlos E. Bueso-Ramos, MD PhD, Sherry R. Pierce, RN, BS, Yue Wei, Guillermo Garcia-Manero, MD

Blood (2014) 124 (21): 3548.

https://doi.org/10.1182/blood.V124.21.3548.3548

Published: 2014

Journal Articles

The Oxazolidinone Derivative Locostatin Induces Apoptosis in CLL Cells through Inhibition of AKT and MAPK-ERK1/2 Signaling Under Conditions That Mimic the Tumor Microenvironment

Oliver Giles Best, PhDBSc, Tahni Pyke, BSc (Hons), Kyle Crassini, MBBS,BSc, William S Stevenson, MBBS, PhD, Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA

Blood (2014) 124 (21): 3326.

https://doi.org/10.1182/blood.V124.21.3326.3326

Published: 2014

Journal Articles

MEK1/2 Inhibition By MEK162 Is Effective Against Chronic Lymphocytic Leukaemia Cells Under Conditions That Mimic Stimulation of B-Cell Receptor-Mediated Signaling

Kyle Crassini, MBBS,BSc, William S Stevenson, MBBS, PhD, Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA, Oliver Giles Best, PhDBSc

Blood (2014) 124 (21): 3330.

https://doi.org/10.1182/blood.V124.21.3330.3330

Published: 2014

Journal Articles

MAPK-Erk1/2 Pathway Activation and Survival Of Chronic Lymphocytic Leukemia (CLL) Cells Is Induced By In Vitro Modeling Of The Tumor Microenvironment and Can Be Effectively Inhibited Using The MEK1 Inhibitor MEK162

O. Giles Best, BSc, PhD, Kyle Crassini, William s Stevenson, MBBS, PhD, Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA

Blood (2013) 122 (21): 4192.

https://doi.org/10.1182/blood.V122.21.4192.4192

Published: 2013

Journal Articles

GFI1B Mutation Causes a Platelet Function Defect With Reduced Alpha-Granule Content and Abnormal Aggregation Response

Christopher M Ward, MB, CHB, PhD, Marie-Christine Morel-Kopp, PhD, Qiang Chen, BMed MSc, Hai Po Liang, PhD, Ashley P. Ng, MBBS, BMedSc, PhD, FRACP, FRCPA, Andrew W. Roberts, MBBS, PhD, Melanie Bahlo, PhD, William s Stevenson, MBBS, PhD

Blood (2013) 122 (21): 566.

https://doi.org/10.1182/blood.V122.21.566.566

Published: 2013

Journal Articles

High Response Rate in Patients with De-Novo or Relapsed/Refractory Acute Myeloid Leukemia Using a Novel Strategy of Low-Dose, Prolonged Administration of Cytarabine and Thioguanine in Combination with Filgrastim in the Ambulatory Setting: A Single-Center, Retrospective Study

Christopher K Arthur, MBBS, FRACP, FRCPA, Brandon Aubrey, MB BS, Matthew Greenwood, MD, FRCPA, FRACP, Keith Fay, MBChB, Luke Coyle, MBBS, FRACP, FRCPA, Eunice Liu, MB BS, Christopher Ward, MB, CHB, PhD, Garry Soo, Naomi Mackinlay, MB BS FRACP FRCPA, William s Stevenson, MBBS, PhD

Blood (2011) 118 (21): 2624.

https://doi.org/10.1182/blood.V118.21.2624.2624

Published: 2011

NARROW

Cdx Report Program: Heterogeneity Revealed in Current Reporting Practices for Hemato-Oncology Companion Diagnostic (CDx) Markers in Multiple Countries

A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis

In Vivo Assessment of Intracellular Dynamics Comparing Injection Versus Oral Azacitidine in a Phase IIb Investigator Initiated Clinical Trial

mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node

Treatment of Elderly and Unfit AML Patients with Prolonged Administration of Low Dose Cytarabine and Thioguanine Achieves High Complete Remission Rates in an Outpatient Setting

Elevated LAG-3 Expression in the Tumor Microenvironement of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis

Deficiencies in Immunoglobulin Classes and Immunoglobulin G Subclasses Are Associated with Shorter Treatment Free Survival and Overall Survival in CLL

Analysis of mRNA Expression in Peripheral, Bone Marrow and Lymph Node Dervied CLL Cells Using the Nanosting Ncounter Platform

Risk Stratification Combining MYC Immunohistochemistry with Standard IPI Has Utility in Patients with Diffuse Large B-Cell Lymphoma

Homozygous Mutation of the ETS DNA-Binding Domain of FLI1 Causes a Bleeding Disorder with Giant Alpha Granules Similar to Paris-Trousseau Thrombocytopenia

Association Between RUNX3 Hypermethylation and Acute Myeloid Leukemia Inv(16) Subtype

The Oxazolidinone Derivative Locostatin Induces Apoptosis in CLL Cells through Inhibition of AKT and MAPK-ERK1/2 Signaling Under Conditions That Mimic the Tumor Microenvironment

MEK1/2 Inhibition By MEK162 Is Effective Against Chronic Lymphocytic Leukaemia Cells Under Conditions That Mimic Stimulation of B-Cell Receptor-Mediated Signaling

MAPK-Erk1/2 Pathway Activation and Survival Of Chronic Lymphocytic Leukemia (CLL) Cells Is Induced By In Vitro Modeling Of The Tumor Microenvironment and Can Be Effectively Inhibited Using The MEK1 Inhibitor MEK162

GFI1B Mutation Causes a Platelet Function Defect With Reduced Alpha-Granule Content and Abnormal Aggregation Response

High Response Rate in Patients with De-Novo or Relapsed/Refractory Acute Myeloid Leukemia Using a Novel Strategy of Low-Dose, Prolonged Administration of Cytarabine and Thioguanine in Combination with Filgrastim in the Ambulatory Setting: A Single-Center, Retrospective Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only